| Name | Clofarabine |
| Description | Clofarabine (Clofarex)m, a second generation purine nucleoside analog with antineoplastic activity, inhibits the enzymatic activities of ribonucleotide reductase (IC50 = 65 nM) and DNA polymerase. |
| In vitro | In athymic nude mice or severe combined immunodeficient (SCID) mice, Clofarabine demonstrates inhibitory effects on various subcutaneously transplanted human tumor xenografts. |
| In vivo | In lymphocytes from chronic lymphocytic leukemia, 10 μM Clofarabine inhibits the repair induced by 4-hydroperoxycyclophosphamide with a peak inhibition at an intracellular concentration of 5 μM. Across a range of leukemia and solid tumor cell lines, Clofarabine demonstrates potent growth inhibition and cytotoxicity (IC50= 0.028–0.29 μM). |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 40 mg/mL (131.72 mM), Sonication is recommended.
|
| Keywords | RR | RNASynthesis | RNA Synthesis | ribonucleotide reductase | NucleosideAntimetabolite | Nucleoside Antimetabolite/Analog | Nucleoside Antimetabolite | nucleoside | Inhibitor | inhibit | DNASynthesis | DNA Synthesis | Clofarabine | Autophagy | Apoptosis | analogue | Analog |
| Inhibitors Related | Stavudine | Sodium 4-phenylbutyrate | L-Ascorbic acid | Hydroxychloroquine | Guanidine hydrochloride | L-Glutamic acid | Tributyrin | Paeonol | Thymidine | Naringin | L-Ascorbic acid sodium salt | Gefitinib |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | EMA Approved Drug Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Anti-Viral Compound Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
United States
